This CPB has been revised to: (i) include in the criteria for initial approval for esketamine nasal spray (Spravato) that the requested medication will be prescribed by or in consultation with a psychiatrist, and (ii) add that Spravato is considered an exclusion for members with moderate or severe substance or alcohol use disorder that is not currently being treated or medically managed (previously listed as experimental and investigational or not medically necessary). This CPB has been updated to remove the appendix and add a dosage and administration section.